Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVAN SUNER

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1164522793
CMS profile
97811
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$91,264.11

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVAN SUNER

NPI 1164522793 · CMS profile ID 97811

Allopathic & Osteopathic Physicians / Ophthalmology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164522793?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVAN SUNER, NPI 1164522793, CMS profile ID 97811. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164522793?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). IVAN SUNER, NPI 1164522793, CMS profile ID 97811. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164522793?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
IVAN SUNER, NPI 1164522793, CMS profile ID 97811, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1164522793?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $91,264.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bausch & Lomb Americas Inc. $103.1007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957488409 CMS
Bausch & Lomb Americas Inc. $87.3407/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957488407 CMS
Genentech USA, Inc. $2,355.0006/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662693 CMS
Bausch & Lomb Americas Inc. $1,500.0005/19/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957488405 CMS
ABBVIE INC. $123.2605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892477045 CMS
Genentech USA, Inc. $842.2005/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675755 CMS
Genentech USA, Inc. $29.8505/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675759 CMS
Genentech USA, Inc. $45.1405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675761 CMS
Genentech USA, Inc. $228.1505/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675765 CMS
Genentech USA, Inc. $123.4705/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675777 CMS
Genentech USA, Inc. $6,280.0005/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950675781 CMS
Genentech USA, Inc. $50.0005/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667095 CMS
Genentech USA, Inc. $117.7604/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667050 CMS
Genentech USA, Inc. $22.9604/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667059 CMS
Genentech USA, Inc. $1,116.3304/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667081 CMS
Genentech USA, Inc. $151.6204/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667105 CMS
Genentech USA, Inc. $11,775.0004/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950667115 CMS
Genentech, Inc. $73.7104/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950781957 CMS
EyePoint Pharmaceuticals US, Inc. $125.0004/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932995097 CMS
Alimera Sciences, Inc. $15.4704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896604163 CMS
Regeneron Healthcare Solutions, Inc. $26.3804/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927435775 CMS
ABBVIE INC. $1,550.0004/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892477043 CMS
Alimera Sciences, Inc. $19.9604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896604791 CMS
Genentech USA, Inc. $20.5004/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950786411 CMS
Genentech USA, Inc. $1,661.8004/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678303 CMS
Genentech USA, Inc. $29.8504/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678305 CMS
Genentech USA, Inc. $36.2204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678309 CMS
Genentech USA, Inc. $158.9204/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678311 CMS
Genentech USA, Inc. $79.3504/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678323 CMS
Genentech USA, Inc. $6,280.0004/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678327 CMS
Horizon Therapeutics plc $112.9504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937702687 CMS
Genentech USA, Inc. $1,474.7304/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679517 CMS
Genentech USA, Inc. $29.8604/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679521 CMS
Genentech USA, Inc. $24.6704/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679525 CMS
Genentech USA, Inc. $161.4104/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679529 CMS
Genentech USA, Inc. $129.1204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679575 CMS
Genentech USA, Inc. $6,280.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950679579 CMS
Regeneron Healthcare Solutions, Inc. $1,080.0003/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927435767 CMS
Bausch & Lomb Americas Inc. $79.1503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957488417 CMS
Regeneron Pharmaceuticals, Inc. $121.1303/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927750217 CMS
Regeneron Healthcare Solutions, Inc. $125.0003/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927435759 CMS
ABBVIE INC. $65.7103/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892477041 CMS
Genentech USA, Inc. $9.1603/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950798199 CMS
Genentech USA, Inc. $94.3603/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950799453 CMS
Genentech USA, Inc. $20.2402/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950802003 CMS
Oyster Point Pharma, Inc. $15.2702/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946065681 CMS
Genentech USA, Inc. $780.0002/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950691247 CMS
Genentech USA, Inc. $780.0002/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950681697 CMS
Regeneron Healthcare Solutions, Inc. $121.1902/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927435751 CMS
Genentech USA, Inc. $137.1801/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950807071 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,641.64 88
PY2020 $37,796.32 37
PY2021 $31,755.08 56
PY2022 $91,264.11 102
PY2023 $71,674.08 93
PY2024 $55,616.11 92
PY2025 $34,203.66 58

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,092.63 2
PY2025 Principal investigator $160,688.88 44
PY2024 Recipient $32,258.90 17
PY2024 Principal investigator $236,322.52 56
PY2023 Principal investigator $350,238.21 105
PY2022 Recipient $3,515.20 1
PY2022 Principal investigator $540,158.07 98
PY2021 Principal investigator $739,967.66 71
PY2020 Recipient $1,942.00 1
PY2020 Principal investigator $867,258.49 84
PY2019 Recipient $2,969.89 1
PY2019 Principal investigator $445,495.41 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $686.34 12/15/2025 Non-covered Recipient Entity
Retina Associates of Florida
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236558
Principal investigator 1 Genentech, Inc. $9,168.00 12/08/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644037
Principal investigator 1 Genentech, Inc. $11.97 11/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644029
Principal investigator 1 Genentech, Inc. $767.36 11/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644033
Principal investigator 1 Genentech, Inc. $385.15 11/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644026
Principal investigator 1 Genentech, Inc. $130.70 10/29/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644022
Principal investigator 1 Genentech, Inc. $6,258.00 10/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643972
Principal investigator 1 Ocular Therapeutix, Inc. $1,690.39 10/15/2025 Non-covered Recipient Entity
Retina Associates of Florida
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236554
Principal investigator 1 Genentech, Inc. $148.89 10/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644018
Principal investigator 1 Genentech, Inc. $69.90 10/06/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644015
Principal investigator 1 Genentech, Inc. $1,705.23 09/29/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643969
Principal investigator 1 Genentech, Inc. $8,567.00 09/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643961
Principal investigator 1 Apellis Pharmaceuticals, Inc. $250.00 09/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363616
Recipient F. Hoffmann-La Roche AG $561.67 09/09/2025 Covered Recipient Physician Association of early macular leakage resolution with extended treatment intervals in patients with RVO: A BALATON/COMINO post hoc analysis No dispute reported 06/30/2026 1211536159
Principal investigator 1 Genentech, Inc. $176.00 08/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643966
Principal investigator 1 Genentech, Inc. $1,640.00 07/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644009
Principal investigator 1 Genentech, Inc. $1,886.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644001
Principal investigator 1 Genentech, Inc. $23.84 07/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644003
Principal investigator 1 Genentech, Inc. $740.97 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644007
Principal investigator 1 Genentech, Inc. $15,744.00 07/07/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643957
Recipient Ocular Therapeutix, Inc. $10,530.96 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229280
Principal investigator 1 Genentech, Inc. $723.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643881
Principal investigator 1 Genentech, Inc. $7,263.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643896
Principal investigator 1 Genentech, Inc. $20,492.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643900
Principal investigator 1 Genentech, Inc. $176.00 06/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643904
Principal investigator 1 Genentech, Inc. $852.29 06/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643978
Principal investigator 1 Genentech, Inc. $10.96 06/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643983
Principal investigator 1 Genentech, Inc. $242.00 06/11/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643892
Principal investigator 1 Genentech, Inc. $168.00 06/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643885
Principal investigator 1 Genentech, Inc. $5,536.00 06/02/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643974
Principal investigator 1 ANI Pharmaceuticals, Inc. $11,014.17 05/15/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA LLC
New Day Study No dispute reported 06/30/2026 1248567431
Principal investigator 1 Genentech, Inc. $43.68 05/02/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643996
Principal investigator 1 Genentech, Inc. $54.04 04/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643993
Principal investigator 1 Genentech, Inc. $1,563.00 04/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643928
Principal investigator 1 Genentech, Inc. $318.00 04/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643936
Principal investigator 1 Genentech, Inc. $504.00 04/16/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643942
Principal investigator 1 Genentech, Inc. $25,989.00 04/11/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643945
Principal investigator 1 Genentech, Inc. $18,958.00 03/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643931
Principal investigator 1 Genentech, Inc. $723.00 03/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643923
Principal investigator 1 Genentech, Inc. $734.00 03/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643950
Principal investigator 1 Genentech, Inc. $568.00 03/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643954
Principal investigator 1 Genentech, Inc. $855.00 02/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643907
Principal investigator 1 Genentech, Inc. $3,795.00 02/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643989
Principal investigator 1 Genentech, Inc. $4,938.00 02/04/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643912
Principal investigator 1 Genentech, Inc. $3,651.00 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643916
Principal investigator 1 Genentech, Inc. $1,468.00 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643920